Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.12 USD | -2.39% | +19.77% | +45.02% |
Jun. 06 | Sector Update: Health Care Stocks Higher in Late Afternoon Trading | MT |
Jun. 06 | Sector Update: Health Care Stocks Advance Thursday Afternoon | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company has insufficient levels of profitability.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+45.02% | 356M | C- | ||
+18.72% | 125B | B+ | ||
+14.19% | 108B | B+ | ||
-4.93% | 24.21B | B+ | ||
+1.16% | 22.78B | B | ||
-10.90% | 17.96B | A- | ||
-41.74% | 16.43B | A- | ||
-13.31% | 16.37B | B | ||
+2.44% | 13.58B | C+ | ||
+27.89% | 11.66B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VNDA Stock
- Ratings Vanda Pharmaceuticals Inc.